非酒精性脂肪肝与心血管疾病的因果证据评估
本文综述非酒精性脂肪肝(NAFLD)与心血管疾病(CVD)因果推断的孟德尔随机化证据。以PNPLA3、TM6SF2和GCKR等基因为工具的研究结果不一致:PNPLA3和TM6SF2变异对冠心病(CAD)有保护作用,GCKR变异则与CAD正相关。这些基因对血浆脂质的差异化效应提示血脂是NAFLD与CVD风险之间的重要中介。
要点
- NAFLD与CVD的关联可能由血浆脂质介导,而非NAFLD本身直接致病。
- PNPLA3和TM6SF2变异降低CAD风险,GCKR变异升高CAD风险,方向与血脂效应一致。
- 12个NAFLD易感基因的扩展分析支持血脂是NAFLD与CVD风险的中介。
核心结论
- 血浆脂质似乎是NAFLD与CVD风险之间的重要中介因素。
研究设计与样本
- 综述类文章,检索范围未在摘要中报告。
主要发现
- 以PNPLA3、TM6SF2和GCKR变异为工具的研究报告了不一致的NAFLD与CAD关联结果。
- PNPLA3和TM6SF2变异对CAD有保护作用,GCKR变异与CAD正相关。
- 三个基因均与脂肪性肝炎相关,提示低度炎症可能介导NAFLD与CAD关系。
- 这些基因对血浆脂质的差异化效应(PNPLA3和TM6SF2降脂,GCKR升脂)与CAD风险方向一致。
- 12个NAFLD易感基因的扩展研究支持血脂作为中介的假说。
临床怎么用
- 设计同时影响脂质代谢的抗NAFLD药物时需考虑其对CVD风险的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent among individuals with type 2 diabetes. Although epidemiological studies have shown that NAFLD is associated with cardiovascular disease (CVD), it remains unknown whether NAFLD is an active contributor or an innocent bystander. Plasma lipids, low-grade inflammation, impaired fibrinolysis and hepatokines are potential mediators of the relationship between NAFLD and CVD. The Mendelian randomisation approach can help to make causal inferences. Studies that used common variants in PNPLA3, TM6SF2 and GCKR as instruments to investigate the relationship between NAFLD and coronary artery disease (CAD) have reported contrasting results. Variants in PNPLA3 and TM6SF2 were found to protect against CAD, whereas variants in GCKR were positively associated with CAD. Since all three genes have been associated with non-alcoholic steatohepatitis, the second stage of NAFLD, the question of whether low-grade inflammation is an important mediator of the relationship between NAFLD and CAD arises. In contrast, the differential effects of these genes on plasma lipids (i.e. lipid-lowering for PNPLA3 and TM6SF2, and lipid-raising for GCKR) strongly suggest that plasma lipids account for their differential effects on CAD risk. This concept has recently been confirmed in an extended set of 12 NAFLD susceptibility genes. From these studies it appears that plasma lipids are an important mediator between NAFLD and CVD risk. These findings have important clinical implications, particularly for the design of anti-NAFLD drugs that also affect lipid metabolism.
引用
- Brouwers MCGJ, Simons N, Stehouwer CDA, et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia. 2019. PMID: 31713012. doi:10.1007/s00125-019-05024-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。